PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Drug Patent Profile

When do Phenylephrine Hydrochloride In 0.9% Sodium Chloride patents expire, and what generic alternatives are available?

Phenylephrine Hydrochloride In 0.9% Sodium Chloride is a drug marketed by Dr Reddys Labs Sa and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is phenylephrine hydrochloride. There are twenty-one drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Phenylephrine Hydrochloride In 0.9% Sodium Chloride

A generic version of PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE was approved as phenylephrine hydrochloride by HIKMA on December 20^th, 2012.

Summary for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	378
DailyMed Link:	PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Applied Biology, Inc.	PHASE3
Follea International Limited	PHASE3
Daniel Alain, Inc.	PHASE3

See all PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE clinical trials

Pharmacology for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Drug Class	alpha-1 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha1-Agonists

US Patents and Regulatory Information for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	216830-001	May 30, 2025		RX	Yes	Yes			Y

International Patents for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

See the table below for patents covering PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2022172253
Argentina	124867

Supplementary Protection Certificates for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1534313	2015/071	Ireland		PRODUCT NAME: AN OCULAR IRRIGATION SOLUTION COMPRISING PHENYLEPHRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND KETOROLAC OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1018 20150728
1534313	15C0090	France		PRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
1534313	92923	Luxembourg		PRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730

Market Dynamics and Financial Trajectory for Phenylephrine Hydrochloride in 0.9% Sodium Chloride

Last updated: January 18, 2026

Summary

Phenylephrine Hydrochloride in 0.9% Sodium Chloride is a widely utilized vasoconstrictor solution primarily used for intravenous (IV) administration to treat hypotension, shock, and nasal decongestion. The global market for this formulation is influenced by increasing demand in hospital care settings, rising prevalence of cardiovascular diseases, and pharmaceutical R&D investments. Market growth is moderated by patent expirations, the availability of generics, and regulatory policies impacting drug pricing and approvals. This report examines the current market landscape, key drivers, restraints, competitive dynamics, and forecasts the financial trajectory through 2030.

---

1. Market Overview

Parameter	Value / Description
Key Indication	Hypotension, shock, nasal congestion
Formulation	Injection (0.9% Sodium Chloride as solvent)
Route of administration	Intravenous
Market value (2022)	Approx. USD 300 million
Expected CAGR (2023-2030)	4.5% - 5.5%
Leading regions	North America, Europe, Asia-Pacific

---

2. Market Drivers

What are the primary factors fueling demand?

• Rising Incidence of Cardiovascular and Hypotensive Conditions
  Globally, the prevalence of hypertension, shock, and other hypotensive states drives consistent demand. According to WHO (World Health Organization), cardiovascular diseases account for approximately 17.9 million deaths annually [1].

• Growing Use in Critical Care Units
  The expansion of ICU facilities worldwide, especially in emerging markets, increases utilization of vasopressors like phenylephrine.

• Increased Preference for Injectable Formulations
  Intravenous routes are preferred in clinical settings for rapid action, ensuring steady growth of injectable phenylephrine solutions.

• Advancements in Hospital Infrastructure
  Upgrades and expansions in healthcare facilities, especially in Asia-Pacific, are propelling the utilization of IV vasoconstrictors.

How does the aging population influence demand?

• The aging global population, particularly in North America and Europe, increases the incidence of conditions requiring vasopressor treatment, bolstering the market.

What regulatory and policy factors impact market growth?

• Stringent approval processes by agencies like FDA, EMA, and NMPA may delay market entry for new formulations but also encourage innovation in existing drugs.

---

3. Market Restraints

What limits growth potential?

• Patent Expirations and Generic Competition
  Several formulations have lost patent protection, leading to price erosion. For instance, phenylephrine formulations common in the U.S. have faced generic proliferation since mid-2010s.

• Pricing Pressures and Healthcare Cost Containment
  Governments and insurers are driving down procurement costs, impacting profit margins for manufacturers.

• Regulatory Challenges for New Formulations
  Stringent clinical trial requirements hinder the introduction of novel variations.

• Availability of Alternatives
  Agents like norepinephrine and epinephrine sometimes replace phenylephrine, especially in shock management, reducing demand.

---

4. Competitive Landscape

Major Industry Players

Company	Market Share (Est.)	Key Products	Strategic Focus
Pfizer (Hospira)	25%	Phenylephrine HCl Injection	Product diversification and biosimilars
Fresenius Kabi	20%	Generic phenylephrine solutions	Cost leadership
Sandoz (Novartis)	15%	Generic vasopressor formulations	Expansion in emerging markets
Hikma Pharmaceuticals	10%	Injectable vasoconstrictors	Strategic collaborations
Others	30%	Multiple regional players	Niche and regional market penetration

Key Mergers & Acquisitions

• Strategic consolidation aims at expanding generics portfolios and regional distribution networks, notably Pfizer's acquisition of GlaxoSmithKline’s sterile injectables portfolio (2021).

---

5. Regional Market Insights

Region	Market Size (2022)	Growth Rate (2023-2030)	Key Factors
North America	USD 120 million	4.8%	Aging population, ICU expansion, high healthcare spending
Europe	USD 80 million	4.2%	Healthcare system modernization, regulatory environment
Asia-Pacific	USD 60 million	6.0%	Increasing healthcare access, rising chronic disease rates
Latin America & Middle East	USD 30 million	5.0%	Growing hospital infrastructure, government initiatives

---

6. Financial Trajectory Forecast (2023-2030)

Year	Estimated Market Size (USD Million)	CAGR	Notes
2023	320	—	Baseline estimate
2024	340	5.0%	Market steady growth
2025	355	4.4%	Increased adoption in emerging markets
2026	370	4.2%	Continued expansion in critical care segments
2027	390	5.4%	R&D investments into novel formulations
2028	410	5.1%	Rising prevalence of cardiovascular conditions
2029	430	4.9%	Growth in hospital infrastructure
2030	450	4.7%	Market matures, with stable growth

---

7. Key Market Trends

• Introduction of Novel Delivery Systems:
  Development of controlled-release IV formulations to optimize dosing and reduce side effects.

• Regulatory Pathways Favoring Biosimilars:
  Increased approval of biosimilar vasopressors to reduce treatment costs.

• Digital Monitoring in Critical Care:
  Integration of real-time monitoring systems enhances safety and efficacy, potentially increasing the use of injectable medications like phenylephrine.

• Emergence of Combination Therapies:
  Combining phenylephrine with other vasoconstrictors or vasodilators for tailored therapy.

---

8. Comparative Analysis with Similar Vasopressors

Parameter	Phenylephrine	Norepinephrine	Epinephrine
Mechanism of Action	Alpha-adrenergic agonist (vasoconstriction)	Alpha & Beta adrenergic agonist	Alpha & Beta adrenergic agonist
Typical Indication	Hypotension, nasal congestion	Shock, severe hypotension	Cardiac arrest, anaphylaxis
Market Size (2022)	Approx. USD 300 million	USD 600 million	USD 500 million
Cost per Dose (Average)	USD 2-3	USD 4-5	USD 5-6
Formulation Stability	Stable, limited side effects	Stable, broad use	Stable, rapid onset

---

9. Regulatory and Policy Considerations

• FDA & EMA Guidelines:
  Emphasize bioequivalence and manufacturing standards for generics.

• Pricing and Reimbursement Policies:
  Encourage cost-effective options; pressure margins for market players.

• Patent Landscape:
  Patent expirations post-2015 increased generic competition, shrinking margins.

• Import/Export Regulations:
  Influence regional availability and market entry.

---

10. Challenges & Opportunities

Challenge	Opportunity
Price erosion from generics	Focus on biosimilars and differentiated formulations
Regulatory delays in new drug approvals	Invest in accelerated approval pathways
Competition from emergent regional players	Expand manufacturing and distribution networks
Supply chain disruptions	Enhance local manufacturing capabilities

---

Key Takeaways

• The phenylephrine in 0.9% sodium chloride market is projected to grow at a CAGR of approximately 4.5–5.5% through 2030, driven by rising healthcare infrastructure and an aging population.
• Market growth is supported by increased ICU expansion, particularly in Asia-Pacific, and the rising burden of cardiovascular conditions.
• Patent expirations and the influx of generics are exerting downward pressure on prices, challenging profitability.
• Competition is intense, with Pfizer, Fresenius Kabi, and Sandoz leading; regional players expanding portfolios.
• Future opportunities include biosimilars, innovative delivery systems, and integration with digital health monitoring.
• Regulatory hurdles and healthcare cost containment measures remain key considerations for market participants.

---

FAQs

Q1: How will patent expirations influence the phenylephrine market?
Patent expirations facilitate generic entry, leading to price reductions and increased volume sales but squeezing profit margins for brand owners. Market players must innovate or diversify portfolios to sustain revenue.

Q2: What are the main regulatory hurdles for new formulations?
Regulatory agencies demand extensive clinical data demonstrating safety, efficacy, and bioequivalence, potentially delaying market entry and increasing development costs.

Q3: How significant is the role of biosimilars in this market?
Biosimilars present a substantial growth opportunity, offering cost-effective alternatives amidst pricing pressures while requiring rigorous regulatory approval.

Q4: Which regions offer the highest growth potential?
Asia-Pacific and Latin America exhibit the highest CAGR, due to expanding healthcare infrastructure and rising disease prevalence.

Q5: What emerging trends could reshape this market?
Development of controlled-release IV formulations, integration of digital health monitoring, and the proliferation of combination therapies are key trends shaping the future landscape.

---

References

[1] WHO. Cardiovascular Diseases (CVDs). World Health Organization; 2021.